Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Charles Stephen Foster, M.D.
EIR
•Charles Stephen Foster, M.D.•May 21, 2018

Charles Stephen Foster, M.D. – FDA EIR, May 21, 2018

Record Details

An FDA Clinical Investigator inspection was conducted at Charles Stephen Foster, M.D., in Waltham, MA, from May 9 to May 21, 2018. This premarket inspection, requested by the FDA's Center for Drug Evaluation and Research, focused on Dr. Foster's conduct of a Phase III clinical study (PSV-FAI-001) for a fluocinolone acetonide intravitreal insert, adhering to regulatory frameworks such as 21 CFR Part 312 for investigational new drugs. The inspection culminated in a Form FDA 483, detailing significant observations. The primary violation cited, under 21 CFR 312.60, was that the investigation was not conducted in accordance with the signed statement of the investigator and the investigational plan. Specifically, the unmasked treating investigator performed safety and efficacy assessments on numerous occasions after Day 1, which was a role designated for the masked investigator, introducing potential bias. Furthermore, a study subject was concurrently enrolled and treated in another ocular inflammation study, conflicting with the protocol's exclusion criteria.Three additional concerns were raised verbally: the site lacked access to an electronic Case Report Form (eCRF) for a transferred subject (violating 21 CFR 312.62(b) regarding case history maintenance), failed to retain monitoring editing notes and all Institutional Review Board (IRB) submissions, and inconsistently documented attending physician confirmations for student-performed eye examinations. Dr. Foster stated he would consider providing a written response to the FDA 483, implying the need for comprehensive corrective actions to address these deviations and ensure robust clinical trial integrity.

Company
Charles Stephen Foster, M.D.
Inspection date
May 21, 2018
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Charles Stephen Foster (investigator)
  • Kent A. Conforti (issuing_officer)
View Company Profile

ID · 99043ff7-6706-41a9-b918-ac590f58c140

Violation Codes2
21 CFR 312.6021 CFR 312.62(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Charles Stephen Foster, M.D.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.